Suppr超能文献

提高高密度昆虫细胞培养中腺相关病毒载体的产量。

Improving adeno-associated vector yield in high density insect cell cultures.

机构信息

Animal Cell Technology Group, Biotechnology Research Institute, National Research Council Canada, Montreal, Quebec, Canada.

出版信息

J Gene Med. 2010 Feb;12(2):157-67. doi: 10.1002/jgm.1420.

Abstract

BACKGROUND

Recombinant adeno-associated virus (rAAV) are the most promising vectors for gene therapy. However, large-scale rAAV production remains a challenge for the translation of rAAV-based therapeutic strategies to the clinic. The baculovirus expression vector system (BEVS) has been engineered to produce high rAAV titers in serum-free suspension cultures of insect cells.

METHODS

The typical approach of rAAV production in BEVS has been based on a synchronous infection with three baculoviruses at high multiplicity of infection (MOI) [>3 plaque forming units (pfu)/cell]. An alternative approach is to co-infect at low MOI (0.1 pfu/cell). Both strategies (high and low MOI) were compared at a cell density of 1.0 x 10(6) cells/ml in shake-flask experiments. To increase the rAAV titer, a low MOI combined with an initial cell density at infection of 5.0 x 10(6) cells/ml, in fed-batch mode, was evaluated. Subsequently, the production strategy was validated in 3-l bioreactor runs.

RESULTS

An increase of 210% in the rAAV titer (4.7 x 10(11) enhanced transduction units/l) was observed when using low MOI, an effect primarily caused by the increase in cell density. The fed-batch approach resulted in a seven-fold increase of rAAV yield. Controlled operations in bioreactor contributed to further increase the rAAV yield (2.8 x 10(14) vector genomes/l) by 25% in comparison to the shake flask results.

CONCLUSIONS

This high yield production process using low MOIs and a feeding strategy successfully addresses several limitations of current rAAV production in insect cells and contributes to position the BEVS system as one of the most efficient for large-scale manufacturing of rAAV vectors.

摘要

背景

重组腺相关病毒(rAAV)是基因治疗最有前途的载体。然而,大规模 rAAV 的生产仍然是将基于 rAAV 的治疗策略转化为临床应用的一个挑战。杆状病毒表达载体系统(BEVS)已被工程化用于在无血清悬浮培养的昆虫细胞中生产高滴度的 rAAV。

方法

BEVS 中 rAAV 的典型生产方法是在高感染复数(MOI)[>3 噬菌斑形成单位(pfu)/细胞]下同步感染三种杆状病毒。另一种方法是低 MOI(0.1 pfu/细胞)共感染。在摇瓶实验中,在细胞密度为 1.0×10(6)个细胞/ml 的条件下,比较了这两种策略(高 MOI 和低 MOI)。为了提高 rAAV 的滴度,在感染时采用低 MOI 并结合初始细胞密度为 5.0×10(6)个细胞/ml 的方法,在补料分批模式下进行了评估。随后,在 3 升生物反应器运行中验证了生产策略。

结果

当使用低 MOI 时,rAAV 的滴度增加了 210%(4.7×10(11)增强转导单位/l),这主要是由于细胞密度的增加所致。补料分批方法使 rAAV 的产量增加了七倍。生物反应器的控制操作进一步将 rAAV 的产量提高了 25%(与摇瓶结果相比,为 2.8×10(14)载体基因组/l)。

结论

使用低 MOI 和进料策略的这种高产生产工艺成功解决了当前昆虫细胞中 rAAV 生产的几个限制,并有助于使 BEVS 系统成为大规模生产 rAAV 载体的最有效系统之一。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验